WO2004043226A2 - Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease - Google Patents
Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease Download PDFInfo
- Publication number
- WO2004043226A2 WO2004043226A2 PCT/US2003/035516 US0335516W WO2004043226A2 WO 2004043226 A2 WO2004043226 A2 WO 2004043226A2 US 0335516 W US0335516 W US 0335516W WO 2004043226 A2 WO2004043226 A2 WO 2004043226A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tau
- patient
- level
- csf
- biological sample
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 142
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 139
- 238000000034 method Methods 0.000 title claims abstract description 116
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 111
- 230000006999 cognitive decline Effects 0.000 claims abstract description 29
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 107
- 102000013498 tau Proteins Human genes 0.000 claims description 70
- 108010026424 tau Proteins Proteins 0.000 claims description 70
- 239000012472 biological sample Substances 0.000 claims description 48
- 230000002861 ventricular Effects 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 18
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 17
- 239000004473 Threonine Substances 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 229940005524 anti-dementia drug Drugs 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 13
- 230000004770 neurodegeneration Effects 0.000 claims description 13
- 238000012937 correction Methods 0.000 claims description 11
- 239000002664 nootropic agent Substances 0.000 claims description 11
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 5
- 238000012034 trail making test Methods 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 description 40
- 238000002595 magnetic resonance imaging Methods 0.000 description 26
- 206010003694 Atrophy Diseases 0.000 description 25
- 230000037444 atrophy Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 10
- 230000032683 aging Effects 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 201000011240 Frontotemporal dementia Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000009593 lumbar puncture Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 210000004727 amygdala Anatomy 0.000 description 6
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 101150037123 APOE gene Proteins 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 201000004810 Vascular dementia Diseases 0.000 description 4
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003140 lateral ventricle Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000007557 neuronal destruction Effects 0.000 description 3
- 230000003557 neuropsychological effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000004097 X-ray Buerger Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101710150365 Albumin-1 Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001076388 Fimbria Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000276398 Opsanus tau Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009601 thyroid function test Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to methods of diagnosing mild cognitive impairment (MCI) in a patient and predicting the rate of cognitive decline in patients who have MCI .
- MCI mild cognitive impairment
- the invention relates to methods of predicting if a patient who has MCI will develop Alzheimer's Disease (AD). More specifically, the invention relates to determining if a patient with MCI is likely to develop AD comprising measuring the level of tau phosphorylated at Threonine 231 (p-tau 23 ⁇ ) in the cerebrospinal fluid (CSF) of the patient.
- AD Alzheimer's Disease
- AD Cerebrospinal fluid
- tau Cerebrospinal fluid
- AD Phosphorylation at threonine 231 of tau has been shown to i be specific for AD and to precede assembly of paired helical filaments in human brain biopsy tissue (Vincent et al . , 1998, Neurobio ., Aging 19_:87-97).
- AD is the leading cause of dementia, and patients with AD have elevated CSF p-tau 231 levels compared with control subjects (Kohnken et al . , 2000, Neurosci .
- Mild Cognitive Impairment is a condition characterized by mild recent memory loss without dementia or significant impairment of other cognitive functions that are beyond what is normal for age or educational background.
- MCI mild cognitive impairment
- MCI is a major risk factor for Alzheimer's Disease (AD) (Petersen et al . , 1995, JAMA 273 :1274-1278) , predicting cognitive decline in patients with MCI is highly desirable to effectively determine which patients might benefit from disease-modifying, anti-dementia drugs.
- AD Alzheimer's Disease
- ,5 invention provides methods for predicting which patients are likely to develop AD by measuring the levels of p-tau 231 in the CSF.
- the invention provides methods of diagnosing mild cognitive impairment (MCI) in a patient and methods of identifying patients who are likely to cognitively deteriorate and develop dementia. Specifically, the invention provides a method of predicting whether a patient will develop Alzheimer's Disease
- the invention also provides a method for determining the stage of neuronal degeneration in a patient who has AD comprising measuring the level of p-tau 23 ⁇ in the CSF of the patient with AD.
- the method of the invention comprises
- CSF cerebrospinal fluid
- p-tau phosphorylated tau
- the level is at least about 250 pg/ml. More
- the level is at least about 300 pg/ml. Most preferably, the level is at least about 350 pg/ml.
- the method further comprises determining the stage of cognitive deterioration of the patient by comparing the level of CSF p-tau with the level of CSF p-tau obtained from
- the p-tau can be a tau protein that is
- the methods of the invention measure the level of tau phosphorylated at threonine 231 (p-tau 23 ⁇ ) , 181, 396, or 404. Most preferably, the methods of the invention measure the level of p-tau 23 ⁇ .
- the invention also provides a method of predicting the rate of neuronal degeneration in a patient comprising the step of determining the level of tau protein phosphorylated at threonine 231 (p-tau 23 i) in a sample of cerebrospinal fluid (CSF) taken from the patient, wherein the patient has Alzheimer's Disease.
- the invention also provides methods of identifying a patient who is likely to develop Alzheimer's Disease comprising:
- the invention provides methods of predicting cognitive decline in a patient, comprising the steps of: (a) obtaining a biological sample from a patient; (b) determining the level of phosphorylated tau protein (p-tau) in the biological sample; (c) identifying the patient as being likely to cognitively decline if the level of p-tau in the biological sample is about 143 pg/ml or higher.
- the invention provides methods of diagnosing Alzheimer's Disease in a patient, comprising the steps of: (a) obtaining a biological sample from a patient; (b) determining the level of p-tau protein in the biological sample; and (c) diagnosing the patient as having Alzheimer's Disease if the level of p-tau in the biological sample is about 215 pg/ml or higher .
- the invention also provides methods of monitoring cognitive decline in a patient comprising the steps of: (a) determining the level of p-tau protein in a biological sample obtained from the patient; (b) determining the p-tau load in the sample by adjusting the p-tau level using a ventricular volume correction;
- step (c) repeating steps (a) and (b) using a subsequently-collected biological sample obtained from the patient; and (d) comparing the p-tau load determined in step (b) with the amount of the p- tau load determined in step (c) and therefrom monitoring cognitive decline in the patient.
- the invention also provides methods of measuring the effectiveness of a pharmaceutical composition as an agent for treating a patient having a condition associated with dementia, comprising the steps of: (a) determining the level of p-tau protein in a biological sample obtained from the a patient; (b) administering an amount of a pharmaceutical composition to the patient; (c) repeating step (a) using a subsequently- collected biological sample obtained from the patient; (d) comparing the level of p-tau protein determined in step (a) with the level of p-tau protein determined in step (c) , wherein the ef ectiveness of the pharmaceutical composition is monitored by detecting no change in the level or p-tau or a decrease in the level of p-tau in the subsequently-collected biological sample compared with the biological sample from step (a) .
- the methods of the invention can be used to identify patients in need of Alzheimer's therapy. For example, once a patient is identified, by a method of the invention, as having or likely to develop Alzheimer's Disease, or is identified as having MCI, or is identified as being likely to cognitively decline, that patient can be subjected to a therapeutic regime for treating Alzheimer's or other dementias.
- An Alzheimer's therapy can include, for example, administering an anti-dementia drug to the patient.
- an anti-dementia drug is an anticholinesterase inhibitor (also referred to herein as an anticholinesterase drug) .
- the invention provides methods of predicting a rate of neuronal degeneration in a patient comprising determining the level of phosphorylated tau (p-tau) protein in a sample of cerebrospinal fluid (CSF) taken from the patient, wherein the patient has Alzheimer's Disease.
- p-tau phosphorylated tau
- p-tau refers to tau protein phosphorylated at amino acid 175, 181, 185, 199, 202, 214, 231, 235, 262, 396, 404, 409, or 422.
- a biological sample used in methods of the invention is cerebrospinal fluid (CSF) .
- Figure 1 depicts a graph showing the correlation between level of p-tau 23 ⁇ in CSF at baseline and annual point loss in MMSE score for 77 patients with mild cognitive impairment (MCI) who were observed during a longitudinal study.
- Figure 2 left panel, shows the right hippocampus (he) and amygdala (ag) manually outlined in a sagittally oriented volumetric MRI section illustrating the localization of both structures.
- Figure 2 right panel, shows a view from right anterior-superior on the right hippocampus and amygdala after manual editing. The depicted MRI scan stems from an AD patient.
- Figure 3 depicts a graph showing that higher levels of CSF tau proteins [pg/ml] correlate with higher baseline volumes of right and left hippocampus [mm 3 ] in AD patients.
- Figure 4 depicts a graph showing that higher CSF p-tau 23 ⁇ levels at baseline [pg/ml] correlate with higher annual rates of right hippocampus atrophy [mm 3 /year] derived from a mixed effects regression model in AD patients.
- p-tau 23 ⁇ concentrations can also be used to identify individuals who are likely to develop
- Alzheimer's Disease particularly individuals who have been previously diagnosed as having mild cognitive impairment (MCI) .
- MCI cerebrospinal fluid
- HC healthy control patients
- High p-tau 23 ⁇ levels at baseline i.e. p-tau 23 i levels at the beginning of the study
- MMSE Mini-Mental State Examination
- t-tau total tau
- Amyloid beta (Reiber, 2001, Clin . Chim. Acta . 310 :173-186) .
- the invention provides a method for monitoring CSF p-tau levels longitudinally (i.e. over a period of time) comprising the step of determining the level of phosphorylated tau protein (p-tau) at various time points and adjusting the level of p-tau at each time point based on the ventricular volume.
- the level adjustment is referred to herein as a "ventricular volume correction.”
- the ventricular volume correction is accomplished by measuring the level of p-tau in the CSF of a patient, multiplying the p-tau concentration (pg/ml) by the ventricular volume (ml) and dividing by 1000.
- Ventricular volume can be determined, for example, by acquiring magnetic resonance imaging (MRI) scans from a patient and converting the MRI signal intensities to ventricular volume using an automated protocol as described by Fox and Freeborough (1997, J. Mag. Reson . Imag. 7:1069-1075).
- An adjusted p-tau level is referred to herein as a p-tau load.
- the p-tau 23 ⁇ load showed a significant longitudinal group-by-time interaction.
- the follow-up tests showed that the p-tau 23 ⁇ load increased in patients with MCI, but did not change in the control group. Moreover, regression analyses of the longitudinal data showed that measuring p-tau 231 load changes significantly improved the prediction of group membership over measuring p-tau 23 ⁇ level changes .
- the rationale for using the ventricular volume correction is based on the understanding that tau levels are higher in the ventricular CSF than in the lumbar CSF. As demonstrated herein, ventricular volume correction is useful only for the p-tau 23 ⁇ measurement. Thus, even though both A ⁇ 40 and p-tau 23 ⁇ levels are elevated in MCI, after applying the ventricular volume correction, a longitudinal change (i.e. change over time) is observed only for the p-tau load in the MCI group.
- the invention provides a method that comprises using the ventricular volume correction to monitor cognitive decline in a patient.
- the method comprises the steps of determining the p-tau load, as described above and in the Examples, in a biological sample (preferably CSF) from the patient at various time points.
- samples can be obtained upon diagnosis of a neurological disorder, such as mild cognitive impairment (MCI) or Alzheimer's Disease (AD), and at various times subsequent to diagnosis, such as every 6 months or annually.
- MCI mild cognitive impairment
- AD Alzheimer's Disease
- Monitoring cognitive decline allows a care provider to determine if a patient is responding well to certain treatments .
- the level of p-tau can be measured in a patient at various times during treatment for MCI or a condition associated with dementia.
- levels of p- tau can be measured at the beginning of treatment with anti-dementia drugs, such as anticholinesterase drugs.
- anticholinesterase drugs include tacrine, donepezil, rivastigmine, and galantamine.
- the level of p-tau can then be monitored at various times, such as weekly, monthly, bi-monthly, or any other chosen time periods, during treatment to determine if the drugs are effective.
- An effective drug will cause the level of p-tau to decrease over time.
- an effective drug will be identified if the level of p-tau does not increase over time.
- Non-limiting examples of conditions associated with dementia include, but are not limited to, Alzheimer's Disease (AD), frontotemporal dementia (FTD) , vascular dementia, Lewy body dementia, or other neuorological disorders.
- the invention provides a method for identifying a patient who has or is likely to develop AD.
- the method comprises the steps of taking a biological sample (preferably a sample of CSF) from a patient, determining the p-tau level (preferably p-tau 23 ⁇ ) in the biological sample, and diagnosing the patient with AD if the p- tau level is about 215 pg/ml or higher.
- the patient can be an individual who has been diagnosed as having mild cognitive impairment (MCI) or any form of dementia, such as frontotemporal dementia (FTD) , vascular dementia, Lewy body dementia, or other neuorological disorders.
- the patient can be an individual who desires or requires screening for AD but who has not been diagnosed with any neurological disorders, dementias, or MCI.
- a method of the invention comprises the steps of taking a biological sample (preferably a sample of CSF) from a patient, determining the p-tau level (preferably p- tau 23 ⁇ ) in the biological sample, and identifying the patient as being likely to develop AD if the level of p-tau in the sample is about 617 pg/ml or higher.
- the level of p-tau indicates a patient who is likely to convert to AD from a more mild neurological disorder.
- the patient can be diagnosed as having MCI prior to being subjected to a method of the invention.
- the invention provides a method of predicting cognitive decline in a patient comprising the steps of taking a biological sample (preferably a sample of CSF) from a patient, determining the p-tau level (preferably p-tau 23 ⁇ ) in the biological sample, and identifying the patient as being likely to develop AD if the level of p-tau in the sample is about 143 pg/ml or higher.
- a biological sample preferably a sample of CSF
- determining the p-tau level preferably p-tau 23 ⁇
- the patient has been diagnosed as having MCI .
- a method of the invention comprises the steps of taking a biological sample (preferably a sample of CSF) from a patient, determining the p-tau 23 ⁇ level in the biological sample, and associating the p-tau 23 ⁇ level with a particular stage of cognitive decline.
- the p-tau 23 i level can be adjusted to determine the p-tau 23 ⁇ ventricular load by correcting the level for CSF ventricular volume, and the p-tau 23 ⁇ load can be associated with a particular stage of cognitive decline.
- CSF cerebrospinal fluid
- the level of phosphorylated tau proteins can be determined in a method of the invention using, for example, an immunoassay or protein-binding assay.
- p-tau 23 ⁇ levels are measured as described herein, using a sandwiched enzyme-linked immunosorbent assay (ELISA) to capture tau protein, then detecting phosporylation of tau with a phosphorylated tau specific antibody (e . g. CP9, which is an antibody specific for p-tau 23 ⁇ ) (see Kohnken et al . , 2000, Neurosci . Lett . 287:187-190) .
- a phosphorylated tau specific antibody e . g. CP9
- a ventricular volume correction can be accomplished as described above to determine the p-tau 23 ⁇ load.
- the ventricular volume can be determined, for example, as described in Example 3 below.
- a method of the invention can be used to determine if a patient has MCI or AD, based on the ventricular p-tau 3 i load.
- the patient can be previously diagnosed as having MCI, and the method of the invention can be used to determine the likelihood of the condition to progress to AD.
- a patient can be examined at follow- up intervals to assess the progression of MCI .
- the methods of the invention can be used alone or in combination with any known diagnostic test(s) and/or marker (s) for diagnosing AD or MCI or for identifying or monitoring cognitive decline, including, but not limited to, mini mental status examination (MMSE) , global deterioration scale (GDS) scores, age, amyloid beta, psycohometric test battery (Kluger et al . 1999, J. Geriat . Psychiat . Neurol . 12:168-179), the Guild Memory Test, the Wechsler adult intelligence scale test, magnetic resonance imaging (MRI), and APOE genotype.
- MMSE mini mental status examination
- GDS global deterioration scale
- age amyloid beta
- MRI magnetic resonance imaging
- APOE genotype APOE genotype.
- Combination with methods of. the invention can increase the sensitivity and decrease the number of false positives of known tests and markers for AD, MCI, and cognitive decline.
- the invention provides methods for examining neuronal degeneration in patients having Alzheimer's disease (AD) .
- AD is characterized by progressive loss of specific neuron populations. The temporal sequence of regional neuron loss is not yet well established. Neuropathological and structural imaging evidence, however, suggests that allocortical areas, including entorhinal cortex, hippocampus and amygdala, are among the earliest affected brain regions in AD.
- the invention provides an in vivo surrogate measure of AD-related neuronal destruction comprising measuring the level of p-tau 23 ⁇ in CSF of patients who have AD.
- CSF P-tau 23 ⁇ correlates with cognitive decline in Mild Cognitive Impairment (MCI) subjects
- MCI mild cognitive impairment
- Phosphorylated tau (p- tau) protein levels were measured by an enzyme-linked immunosorbent assays (ELISA) as described in Kohnken et al . (Kohnken et al . , 2000, Neurosci . Lett . 287:187-190) using an anti-p-tau 23 i antibody (Molecular Geriatrics Corporation, Vernon Hills, IL, USA) . Levels of t-tau were measured by ELISA using the Innotest hTau kit (art. no. K-1032; Innogenetics, Zwjindrecht, Belgium). Data were reported as means +SD. The APOE genotype was determined according to standard procedures .
- the yearly point loss in MMSE score was modeled with stepwise multiple linear regression to generate a multiple regression model (see Figure 1) .
- the independent variables were baseline p-tau 23 ⁇ levels, MMSE score, age, as well as sex, APOE genotype as a two-level variable (0 vs 1/2 e4 alleles) , center, treatment with cognitive enhancers, and time of follow-up.
- p-tau 2 3i was replaced by t-tau.
- MCI who converted to AD during follow-up (MCI converters; 617 ⁇
- the limits of the 95% CI for the group difference ranged from -43 pg/mL to 281 pg/mL for p-tau 231 levels and from - 22 pg/mL to 242 pg/mL for t-tau levels.
- CSF levels of p-tau 23 ⁇ can distinguish AD from other dementias
- One-hundred and ninety-two (192) patients with a clinical diagnosis of AD, frontotemporal dementia (FTD) , vascular dementia, Lewy body dementia, or other neuorolgical disorder and healthy controls were selected and levels of t-tau and p-tau 231 in the CSF were determined as described above .
- the mean CSF levels of p-tau 23 ⁇ were significantly elevated in the AD group compared with all other groups.
- the level of p-tau 231 discriminated with a sensitivity of 90.2% and a specificity of 80.0% between AD and all non-AD disorders.
- the cutoff level of p-tau 23 i yielding the best sensitivity and specificity for discriminating patients with AD from those with non-AD disease and healthy controls was about 215 pg/ml.
- a p-tau 23i CSF level of about 215 pg/ml or higher can distinguish AD from non-AD dementias.
- Ventricular volume of p-tau 23 ⁇ increases in patients with mild cognitive impairment Ten normal elderly volunteers and eight patients (seven MCI and one very mild AD) were subjected at baseline and after 1 year to a screening and diagnostic evaluation that included: medical (history, physical, and laboratory), neurological, psychiatric, and neuropsychological examinations, MRI, and lumbar puncture (LP) . The annual evaluations were completed within a 2 month window.
- GDS global deterioration scale
- the psychometric test battery (as described in Kluger et al . , 1999, J. Geriat . Psychiat . Neurol . 12:168-179) included evaluation of memory (immediate and 10 min delayed recall from the paragraph and the paired associates subtests of the Guild Memory Test) and attention/psychomotor speed (the Digit-Symbol Substitution Test of the Wechsler adult intelligence scale- revised test) .
- Magnetic resonance imaging (MRI) scans were acquired using a 1.5 T GE Signa imager.
- a clinical MRI examination covered the entire brain with contiguous 3 mm axial T2- weighted images.
- Scan signal intensities were normalized with reference to white matter intensity.
- the baseline and follow-up images were co-registered and reformatted in one sine interpolation step to a 1.5 mm slice thickness oriented to a standard plane.
- a three-dimensional region was constructed to span the baseline and the follow-up ventricular CSF that excluded subarachnoid CSF. Following the technique of Fox and Freeborough (1997, J " . Mag. Reson . Imag. 1069-1075) , an automated protocol was applied to the region to segment CSF from surrounding brain tissue at baseline and follow-up.
- IS signal intensities were converted to ' the '' CSF " volume using the partial volume decomposition method.
- a sandwich enzyme-linked immunosorbent assay was L0 used to detect tau phosphorlyated at threonine 231 (p-tau 23 i) in CSF.
- tau was captured with two backbone-directed antibodies, tau-1 and CP-27. The captured tau was then detected by CP9, which is specific for p-tau 23 ⁇ (Kohnken et al . , 2000, Neurosci . Lett . 287:187-190).
- the detection limit for this L5 assay was 9 pg/ml .
- the coefficients of variation ranged from 6.0-10.3% (intra-assay) and 11.6-14.4% (inter-assay).
- CSF A ⁇ levels were measured using monoclonal antibody 6E10 (specific to an epitope present on A ⁇ -16) and to rabbit antisera to A ⁇ 40 and A ⁇ 42, respectively in a double antibody sandwich 20 ELISA (Kohnken et al . , 2000, Neurosci . Lett . 287:187-190) .
- the detection limit for A ⁇ 40 and A ⁇ 42 was 10 pg/ml.
- the reproducibility ranged from 8 to 14% (intra-assay) and 10-18% (interassay) .
- the load of p-tau 23 i (ng) in the CSF was estimated by. 25 multiplying the p-tau 23 i concentration (pg/ml) by the ventricular volume (ml) and dividing by 1000.
- W ventricle volume ; Ptau, p-tau 23 ⁇ ,- A ⁇ amyloid beta ; cc , cubic centimeter
- a ⁇ 42 levels did not differ between the groups. No longitudinal changes were observed for any CSF level measure (P > 0.05) .
- the cross-sectional data show that two markers of AD pathology (p-tau 23 ⁇ and A ⁇ 40) are elevated in MCI. Longitudinally, only the p-tau 23 ⁇ increases in MCI, as detected by correcting for the change in ventricle size.
- Example 4 p-tau 23 ⁇ in the CSF of patient's who have AD Twenty-two patients with the clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria were selected. For comparison of baseline MRI measures, 21 healthy volunteers were selected. Subjects were recruited from the Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Dementia and Imaging Research Section, Ludwig-Maximilian Unirversity Kunststoff, Germany. Subject characteristics are given in Table 4.
- AD patients and controls Significant medical co-morbidity in the AD patients and controls was excluded by history, physical and neurological examination, psychiatric evaluation, chest X-ray, ECG, EEG, brain MRI, and laboratory tests (complete blood count, sedimentation rate, electrolytes, glucose, blood urea nitrogen, creatinine, liver-associated enzymes, cholesterol, HDL, triglycerides, antinuclear antibodies, rheumatoid factor, VDRL, HIV, serum B12, folate, thyroid function tests and urine analysis) .
- Two AD patients had mild hypertension, no subject had diabetes. With exception of one patient, all AD patients received state of the art anti-dementive treatment during clinical follow up.
- volumetric analysis was performed with the interactive software package DISPLAY developed at the Brain Imaging Center. This program allows simultaneous visualization and segmentation of volumes in coronal, sagittal and horizontal orientations.
- FIG. 2 shows the localization and morphology of the hippocampus.
- the most posterior part of the HC was defined as the first appearance of gray matter inferiomedial to the trigone of the lateral ventricle (TLV) in the caudorostral extent of the HC.
- the lateral border in the tail of the HC was the TLV.
- the border of the HC was identified by white matter.
- an arbitrary border was defined for the superior and medial border of the HC, in order to differentiate HC gray matter from the gray matter of the Andreas Retzius gyrus, the fasciolar gyrus, and the crus of the fornix.
- the inferior border of the HC at this point was again identified by white matter.
- the whit " e “”” mat " fcer ba ⁇ cTal; the superolateral level of the HC, the fimbria was included.
- the lateral border at this point was identified by the inferior horn of the lateral ventricle.
- the quadrogeminal cistern defined the superomedial border of the HC.
- the most important structures for identification of 0 lateral, anterior and superior borders of the HC head were the uncal recess of the inferior horn of the lateral ventricle and the alveus . Besides the coronal view, the sagittal and horizontal views were employed for identification of the anterior border of the HC head.
- 5 Inter-rater reliability was assessed using four raters independently measuring the same set of 5 MRI scans . The coefficient of variation between the raters ranged between 1.8% and 2.2% for right and left hippocampus. The intraclass correlation coefficients ranged between 0.94 and 0.86 for right 0 and left hippocampus. The intra-rater reliability was determined by one rater measuring four times the same set 5 MRI scans within a previously not measured set of MRI scans . The coefficients of variation within rater ranged between 2.2 % and
- the intraclass 5 correlation coefficients ranged between 0.91 and 0.94 for right and left hippocampus .
- Tau protein levels were measured using enzyme-linked immunosorbent assays (ELISA) as described above.
- Rates of atrophy of left and right hippocampus were determined with mixed effect regression models using SAS 8.02 Proc Mixed software (SAS Institute Inc., Cary, NC, USA).
- each volume (right and left hippocampus) was predicted by a mixed effect regression term, incorporating random-effect terms to account for subject and subject by time differences in volumes (random trend model) .
- the random trend model conceptualizes each patient's volume change as following a straight line parameterized by a slope and an intercept. The slope measures the patient ' s rate of atrophy, the intercept the patient's baseline volume. Individual slopes and intercepts are regarded as a random sample of a normal population with unknown mean and variance.
- Hippocampus volumes were significantly reduced in AD patients compared to controls (p ⁇ 0.003 for all comparisons). These effects remained significant after controlling for age differences between groups using a multiple regression model (p ⁇ 0.05) . Hippocampal volumes are shown in Table 5. In the AD group, levels of p-tau 23 ⁇ were 729.6 (SD 404.3) pg/ml, and levels of t-tau were 608.1 (SD 314.6) pg/ml. Annual rates of atrophy in the AD patients were about 14% for right anTTeft hippocampus (Table 6) .
- Patient and control groups were matched for gender distribution, but were different in age (Table 4) .
- tau protein levels in CSF may reflect the degree of axonal and neuronal destruction in AD, which is the main determinant of subsequent morphological disease progression as visualized with structural MRI .
- Levels of p-tau 23 ⁇ predicted the rate of subsequent hippocampus atrophy, accounting for about 20 % of variability in individual rates of atrophy.
- Levels of t-tau were not predictive for subsequent rates of atrophy.
- the degree of neuronal degeneration at a given time period may be highly predictive for the rate of neuronal loss in the subsequent time period.
- the rate of neuronal loss m "AD ' can be assessed in vivo by MRI based measurement of atrophy, since it has been shown that hippocampus atrophy in MRI accounts for 80% of variability of neuronal cells numbers in hippocampus in AD.
- the significant correlations between p-tau 23 i levels and rates of hippocampal atrophy suggest that CSF levels of p-tau 231 can serve as a state marker for the degree of neuronal destruction in AD which in turn determines subsequent rates of neuronal loss and regional atrophy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004551856A JP2006517650A (en) | 2002-11-07 | 2003-11-07 | Method for predicting whether a subject with mild cognitive impairment (MCI) will develop Alzheimer's disease |
CA002505355A CA2505355A1 (en) | 2002-11-07 | 2003-11-07 | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
MXPA05004828A MXPA05004828A (en) | 2002-11-07 | 2003-11-07 | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease. |
EP03768751A EP1626648A4 (en) | 2002-11-07 | 2003-11-07 | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer s disease |
AU2003291358A AU2003291358A1 (en) | 2002-11-07 | 2003-11-07 | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42462802P | 2002-11-07 | 2002-11-07 | |
US60/424,628 | 2002-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004043226A2 true WO2004043226A2 (en) | 2004-05-27 |
WO2004043226A3 WO2004043226A3 (en) | 2007-07-05 |
Family
ID=32312845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/035516 WO2004043226A2 (en) | 2002-11-07 | 2003-11-07 | Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease |
Country Status (7)
Country | Link |
---|---|
US (2) | US20040166536A1 (en) |
EP (1) | EP1626648A4 (en) |
JP (1) | JP2006517650A (en) |
AU (1) | AU2003291358A1 (en) |
CA (1) | CA2505355A1 (en) |
MX (1) | MXPA05004828A (en) |
WO (1) | WO2004043226A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10393759B2 (en) | 2011-04-12 | 2019-08-27 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645898B2 (en) | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
JP2011502966A (en) * | 2007-10-31 | 2011-01-27 | アルセレス ファーマシューティカルズ, インコーポレイテッド | Method for the diagnosis of Lewy body dementia by assessing dopamine transporter levels and the monitoring of Lewy body dementia treatment |
WO2009095454A2 (en) * | 2008-02-01 | 2009-08-06 | Brahms Aktiengesellschaft | Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients |
CA2731247A1 (en) * | 2008-07-25 | 2010-01-28 | Merck Sharp & Dohme Corp. | Csf biomarkers for the prediction of cognitive decline in alzheimer's disease patients |
ITRM20130253A1 (en) * | 2013-04-29 | 2014-10-30 | Canox4Drug S P A | METHOD FOR DETERMINING FREE COPPER |
TWI708058B (en) * | 2013-10-24 | 2020-10-21 | 美商納諾索米克斯公司 | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders |
US10282875B2 (en) | 2015-12-11 | 2019-05-07 | International Business Machines Corporation | Graph-based analysis for bio-signal event sensing |
WO2018008764A1 (en) * | 2016-07-08 | 2018-01-11 | 味の素株式会社 | Method for evaluating mild cognitive impairment or alzheimer's type dementia |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
EP3731749A4 (en) | 2017-12-31 | 2022-07-27 | Neuroenhancement Lab, LLC | System and method for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
WO2019213245A1 (en) * | 2018-05-03 | 2019-11-07 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
US10740655B2 (en) * | 2018-07-02 | 2020-08-11 | Centre Hospitalier Universitaire Vaudois | Integrative prediction of a cognitive evolution of a subject |
EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US20220073986A1 (en) * | 2018-09-18 | 2022-03-10 | Vivid Genomics, Inc. | Method of characterizing a neurodegenerative pathology |
WO2020144575A1 (en) * | 2019-01-08 | 2020-07-16 | Iluria Ltd. | Diagnosis and effectiveness of monitoring attention deficit hyperactivity disorder |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
CN113827191B (en) * | 2021-09-29 | 2024-01-23 | 上海市精神卫生中心(上海市心理咨询培训中心) | Method, device, processor and computer storage medium for realizing quick screening of cognitive impairment of old people by using layering progressive mode |
WO2024097164A1 (en) * | 2022-10-31 | 2024-05-10 | North Carolina Central University | Phospho-tau aggregation-based biomarkers for alzheimer's disease diagnosis, differentiation, and treatment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492812A (en) * | 1991-08-01 | 1996-02-20 | Provost, Fellows And Scholars Of Trinity College | Diagnostic method for Alzheimer's disease by screening for tau-peptides in the blood of a patient |
-
2003
- 2003-11-07 EP EP03768751A patent/EP1626648A4/en not_active Withdrawn
- 2003-11-07 JP JP2004551856A patent/JP2006517650A/en active Pending
- 2003-11-07 US US10/704,233 patent/US20040166536A1/en not_active Abandoned
- 2003-11-07 AU AU2003291358A patent/AU2003291358A1/en not_active Abandoned
- 2003-11-07 MX MXPA05004828A patent/MXPA05004828A/en not_active Application Discontinuation
- 2003-11-07 WO PCT/US2003/035516 patent/WO2004043226A2/en active Application Filing
- 2003-11-07 CA CA002505355A patent/CA2505355A1/en not_active Abandoned
-
2008
- 2008-05-02 US US12/114,087 patent/US20090022825A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492812A (en) * | 1991-08-01 | 1996-02-20 | Provost, Fellows And Scholars Of Trinity College | Diagnostic method for Alzheimer's disease by screening for tau-peptides in the blood of a patient |
Non-Patent Citations (2)
Title |
---|
KOHNKEN R. ET AL.: 'Detection of Tau Phosphorylated at Threonine 231 in Cerebrospinal Fluid of Alzheimer's Disease Patients' NEUROSCI. LETT. vol. 287, 2000, pages 187 - 190, XP000952991 * |
See also references of EP1626648A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10393759B2 (en) | 2011-04-12 | 2019-08-27 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
US11275092B2 (en) | 2011-04-12 | 2022-03-15 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
Also Published As
Publication number | Publication date |
---|---|
US20090022825A1 (en) | 2009-01-22 |
AU2003291358A8 (en) | 2004-06-03 |
CA2505355A1 (en) | 2004-05-27 |
EP1626648A2 (en) | 2006-02-22 |
JP2006517650A (en) | 2006-07-27 |
WO2004043226A3 (en) | 2007-07-05 |
US20040166536A1 (en) | 2004-08-26 |
MXPA05004828A (en) | 2006-01-27 |
EP1626648A4 (en) | 2010-04-28 |
AU2003291358A1 (en) | 2004-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090022825A1 (en) | Method for Predicting Whether Subjects With Mild Cognitive Impairment (MCI) Will Develop Alzheimer's Disease | |
Pennanen et al. | Hippocampus and entorhinal cortex in mild cognitive impairment and early AD | |
Coblentz et al. | Presenile dementia: Clinical aspects and evaluation of cerebrospinal fluid dynamics | |
De Leon et al. | MRI and CSF studies in the early diagnosis of Alzheimer's disease | |
O'BRIEN et al. | Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment | |
Laske et al. | Innovative diagnostic tools for early detection of Alzheimer's disease | |
De Leon et al. | Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease | |
Killiany et al. | Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease | |
De Leon et al. | The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. | |
Stoub et al. | Rate of entorhinal and hippocampal atrophy in incipient and mild AD: Relation to memory function | |
Convit et al. | Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease | |
Krasuski et al. | Volumes of medial temporal lobe structures in patients with Alzheimer’s disease and mild cognitive impairment (and in healthy controls) | |
Wolf et al. | Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly | |
Resnick et al. | Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts | |
LeMay et al. | Statistical assessment of perceptual CT scan ratings in patients with Alzheimer type dementia | |
Steffens et al. | Biological and social predictors of long-term geriatric depression outcome | |
Sparks et al. | Tau is reduced in AD plasma and validation of employed ELISA methods | |
Anstey et al. | The role of volumetric MRI in understanding mild cognitive impairment and similar classifications | |
US20130310682A1 (en) | CSF Biomarker Dilution Factor Corrections by MRI Imaging and Algorithm | |
US5545566A (en) | Antemortem diagnostic test for alzheimer's disease | |
Prasher | Dementia questionnaire for persons with mental retardation (DMR): modified criteria for adults with Down's syndrome | |
Kitagaki et al. | Alteration of white matter MR signal intensity in frontotemporal dementia. | |
Rizzolo et al. | Relationship between brain AD biomarkers and episodic memory performance in healthy aging | |
Herukka et al. | CSF Aβ42, tau and phosphorylated tau correlate with medial temporal lobe atrophy | |
Alm et al. | Medial temporal lobe white matter pathway variability is associated with individual differences in episodic memory in cognitively normal older adults |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/004828 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2505355 Country of ref document: CA Ref document number: 2004551856 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003768751 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003768751 Country of ref document: EP |